8-K Announcements
6Material company update
Aug 5, 2025·SEC
Material company update
Jul 23, 2025·SEC
Material company update
Jul 16, 2025·SEC
Ocean Biomedical, Inc.(OCEA)Earnings, Financials & Key Ratios
OCEA•NASDAQ
Price updated Jun 19, 2026
AboutOcean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.Show more
- Revenue$0
- EBITDA$0+100.0%
- Net Income-$3M-683.8%
- EPS (Diluted)-0.12-153.2%
- ROE-98.81%-18408.4%
OCEA Key Insights
Ocean Biomedical, Inc. (OCEA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 0/9
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Shares diluted 44.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OCEA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OCEA Price & Volume
Ocean Biomedical, Inc. (OCEA) stock price & volume — 10-year historical chart
Loading chart...
OCEA Growth Metrics
Ocean Biomedical, Inc. (OCEA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM0.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM3.45%
Return on Capital
10 Years-1.68%
5 Years-1.68%
3 Years-1.68%
Last Year-
OCEA Peer Comparison
Ocean Biomedical, Inc. (OCEA) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 KALA | 79.17M | 3.61 | -1.09 | -13.36% | ||||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 NUVB | 1.93B | 5.56 | -9.27 | 6.99% | -102.06% | -44.1% | 0.03 | |
 ADMA | 1.93B | 8.31 | 13.85 | 19.63% | 32.43% | 38.97% | 0.17 | |
 SNDX | 1.68B | 19.00 | -5.78 | 6.28% | -112.01% | -256.66% | 5.36 | |
 LUNG | 54.06M | 1.28 | -0.96 | 8.01% | -59.67% | -82.79% | 1.04 |
Compare OCEA vs Peers
Ocean Biomedical, Inc. (OCEA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OCEA Income Statement
Ocean Biomedical, Inc. (OCEA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - |
Operating Expenses | 232K | 1.65M | 566.56K | 2.48M | 3.8M | 4.16M |
OpEx % of Revenue | - | - | - | - | - | - |
Selling, General & Admin | 197K | 1.6M | 28.41M | 2.48M | 3.77M | 4.14M |
SG&A % of Revenue | - | - | - | - | - | - |
Research & Development | 35K | 49K | 33.93M | 0 | 26K | 18K |
R&D % of Revenue | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | -61.78M | 0 | 0 | 0 |
Operating Income | -232K▲ 0% | -1.65M▼ 612.1% | -566.56K▲ 65.7% | -2.48M▼ 338.0% | 0▲ 100.0% | -363K▲ 0% |
Operating Margin % | - | - | - | - | - | - |
Operating Income Growth % | - | -612.07% | 65.7% | -338.02% | 100% | - |
EBITDA | -60.14K | -1.45M | -330K | -957.74K | 0 | -28.97M |
EBITDA Margin % | - | - | - | - | - | - |
EBITDA Growth % | - | -2303.9% | 77.17% | -190.22% | 100% | -50.91% |
D&A (Non-Cash Add-back) | 171.86K | 206.3K | 236.56K | 0 | 0 | 0 |
EBIT | 0 | 0 | -564.11K | -957.74K | 0 | -28.97M |
Net Interest Income | 0 | 0 | 2.45K | 1.52M | 0 | -1.75M |
Interest Income | 0 | 0 | 2.45K | 1.52M | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 691 | -2.05M | 1.75M |
Other Income/Expense | 0 | -1K | 2.45K | 1.52M | 0 | -24.18M |
Pretax Income | -232K▲ 0% | -1.65M▼ 612.5% | -564.11K▲ 65.9% | -958.43K▼ 69.9% | -3.3M▼ 244.4% | -24.54M▲ 0% |
Pretax Margin % | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | -3.3M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 13.45% |
Net Income | -232K▲ 0% | -1.65M▼ 612.5% | -62.34M▼ 3671.6% | 565.47K▲ 100.9% | -3.3M▼ 683.8% | -30.72M▲ 0% |
Net Margin % | - | - | - | - | - | - |
Net Income Growth % | - | -612.5% | -3671.57% | 100.91% | -683.76% | 0.82% |
Net Income (Continuing) | -232K | -1.65M | -564.11K | -958.43K | -3.3M | -21.24M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.01▲ 0% | -0.08▼ 611.3% | -0.04▲ 47.9% | -0.05▼ 11.3% | -0.12▼ 153.2% | -1.12▲ 0% |
EPS Growth % | - | -611.3% | 47.92% | -11.27% | -153.16% | 3.45% |
EPS (Basic) | -0.01 | -0.08 | -0.04 | -0.05 | -0.12 | - |
Diluted Shares Outstanding | 20.2M | 20.2M | 13.22M | 19.02M | 27.5M | 27.5M |
Basic Shares Outstanding | 20.2M | 20.2M | 13.22M | 19.02M | 27.5M | 27.5M |
Dividend Payout Ratio | - | - | - | - | - | - |
OCEA Balance Sheet
Ocean Biomedical, Inc. (OCEA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 0 | 386K | 1.55M | 467.99K | 812K | 1.49M |
Cash & Short-Term Investments | 0 | 0 | 1.08M | 328.31K | 0 | 0 |
Cash Only | 0 | 0 | 1.08M | 328.31K | 0 | 0 |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 50K | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 0 | 386K | 0 | 0 | 224K | 777K |
Total Non-Current Assets | 0 | 0 | 107.1M | 110.44M | 90K | 90K |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 107.1M | 110.44M | 90K | 844K |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 0▲ 0% | 386K▲ 0% | 108.65M▲ 28048.3% | 110.91M▲ 2.1% | 902K▼ 99.2% | 1.58M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.00x |
Asset Growth % | - | - | 28048.28% | 2.08% | -99.19% | -211.26% |
Total Current Liabilities | 232K | 2.27M | 246.44K | 3.46M | 33.89M | 26.57M |
Accounts Payable | 0 | 53K | 34.44K | 0 | 799K | 964K |
Days Payables Outstanding | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 2.15M | 16.3M | 9.35M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | -232K | 0 | 0 | 0 | 1.09M | 198K |
Current Ratio | - | 0.17x | 6.29x | 0.14x | 0.02x | 0.06x |
Quick Ratio | - | 0.17x | 6.29x | 0.14x | 0.02x | 0.06x |
Cash Conversion Cycle | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 53K | 3.15M | 3.15M | 64.63M | 67.41M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 64.63M | 67.41M |
Total Liabilities | 232K | 2.27M | 3.4M | 6.61M | 98.52M | 93.98M |
Total Debt | 0 | 0 | 0 | 2.15M | 16.3M | 9.35M |
Net Debt | 0 | 0 | -60K | 1.82M | 16.3M | 9.35M |
Debt / Equity | - | - | - | 0.02x | - | -0.10x |
Debt / EBITDA | - | - | - | - | - | -0.32x |
Net Debt / EBITDA | - | - | - | - | - | -0.32x |
Interest Coverage | - | - | - | -1386.02x | - | -16.53x |
Total Equity | -232K▲ 0% | -1.89M▼ 712.5% | 105.26M▲ 5683.9% | 104.3M▼ 0.9% | -97.62M▼ 193.6% | -92.4M▲ 0% |
Equity Growth % | - | -712.5% | 5683.87% | -0.91% | -193.59% | -1063.82% |
Book Value per Share | -0.01 | -0.09 | 7.96 | 5.48 | -3.55 | -3.36 |
Total Shareholders' Equity | -232K | -1.89M | 105.26M | 104.3M | -97.62M | -92.4M |
Common Stock | 0 | 0 | 107.1M | 110.44M | 0 | 0 |
Retained Earnings | -232K | -1.89M | -564.11K | -2.77M | -205.53M | -213.78M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
OCEA Cash Flow Statement
Ocean Biomedical, Inc. (OCEA) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | 0 | -64K | -1.05M | -747.3K | -4.18M | -4.05M |
Operating CF Margin % | - | - | - | - | - | - |
Operating CF Growth % | - | - | -1545.31% | 29.03% | -459.35% | -48.78% |
Net Income | -232K | -1.65M | -62.34M | -958.43K | -9.48M | -30.72M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 0 | 0 | 56.55M | 0 | 745K | 931K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 0 | 0 | -1.52M | 3.51M | 25.54M |
Working Capital Changes | 232K | 1.59M | 4.74M | 1.74M | 1.04M | 198K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 290.38K | 869K | 957K |
Cash from Investing | 0 | 0 | -107.1M | -2.1M | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | -3 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 3 | 0 | 0 |
Cash from Financing | 0 | 64K | 1.11M | 2.1M | 3.4M | 4.31M |
Debt Issued (Net) | 0 | 0 | 0 | 2.1M | 3.4M | 909K |
Equity Issued (Net) | 0 | 0 | 1.02M | 0 | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 64K | 96K | 0 | 0 | 3.4M |
Net Change in Cash | 0▲ 0% | 0▲ 0% | 60K▲ 0% | -747.3K▼ 1345.5% | -780K▼ 4.4% | 258K▲ 0% |
Free Cash Flow | 0▲ 0% | -64K▲ 0% | -1.05M▼ 1545.3% | -747.3K▲ 29.0% | -4.18M▼ 459.3% | -4.05M▲ 0% |
FCF Margin % | - | - | - | - | - | - |
FCF Growth % | - | - | -1545.31% | 29.03% | -459.35% | 44.22% |
FCF per Share | - | -0.00 | -0.08 | -0.04 | -0.15 | -0.15 |
FCF Conversion (FCF/Net Income) | - | 0.04x | 0.02x | -1.32x | 1.27x | 0.13x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
OCEA Key Ratios
Ocean Biomedical, Inc. (OCEA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2024 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | - | -120.62% | 0.54% | -98.81% | 32.26% |
Return on Invested Capital (ROIC) | - | -0.83% | -1.77% | - | 0.33% |
Debt / Equity | - | - | 0.02x | - | -0.10x |
Interest Coverage | - | - | -1386.02x | - | -16.53x |
FCF Conversion | 0.04x | 0.02x | -1.32x | 1.27x | 0.13x |
Related:OCEA Dividend History·OCEA Revenue History·OCEA Price History·OCEA P/E History·OCEA Financial Ratios·OCEA Institutional Holders
OCEA SEC Filings & Documents
Ocean Biomedical, Inc. (OCEA) SEC filings — annual & quarterly reports (10-K, 10-Q)
OCEA Frequently Asked Questions
Ocean Biomedical, Inc. (OCEA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ocean Biomedical, Inc. (OCEA) grew revenue by 0.0% over the past year. Growth has been modest.
Ocean Biomedical, Inc. (OCEA) reported a net loss of $30.7M for fiscal year 2024.
Dividend & Returns
Ocean Biomedical, Inc. (OCEA) has a return on equity (ROE) of -98.8%. Negative ROE indicates the company is unprofitable.
Ocean Biomedical, Inc. (OCEA) had negative free cash flow of $4.1M in fiscal year 2024, likely due to heavy capital investments.